Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Bacterial Skin and Skin Structure Infections: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Acute Bacterial Skin and Skin Structure Infections: 3 US clinical trials tracked, none currently recruiting.
Acute Bacterial Skin and Skin Structure Infections is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Arrevus, running 1 of these trials.
Enrollment posture brief
Registry condition acute-bacterial-skin-and-skin-structure-infections
OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Acute Bacterial Skin and Skin Structure Infections has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Bacterial Skin and Skin Structure Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Bacterial Skin and Skin Structure Infections is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Arrevus
NCT02570490
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Basilea Pharmaceutica
NCT03137173
Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Novexel
NCT00949130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Bacterial Skin and Skin Structure Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Bacterial Skin and Skin Structure Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Bacterial Skin and Skin Structure Infections page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Acute Bacterial Skin and Skin Structure Infections trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Arrevus sponsors the most Acute Bacterial Skin and Skin Structure Infections trials on record, review their full trial history before evaluating a specific study. See Arrevus's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Bacterial Skin and Skin Structure Infections condition card totals 3 registered trials; most-linked intervention sodium fusidate; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.